IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0233510
(2012-07-17)
|
등록번호 |
US-9775825
(2017-10-03)
|
우선권정보 |
IN-2058/MUM/2011 (2011-07-19) |
국제출원번호 |
PCT/IB2012/053646
(2012-07-17)
|
§371/§102 date |
20140117
(20140117)
|
국제공개번호 |
WO2013/011458
(2013-01-24)
|
발명자
/ 주소 |
- Bhaskaran, Sunil
- Vishwaraman, Mohan
|
출원인 / 주소 |
- Indus Biotech Private Limited
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
2 |
초록
▼
The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along wi
The present disclosure is related to management of chemotherapy induced side effects namely cachexia and alopecia by administering a pharmaceutical composition comprising pentameric type A procyanidin flavonoid, trimeric procyanidin flavonoid and tetrameric procyanidin flavonoid, optionally along with pharmaceutical excipients.
대표청구항
▼
1. A method of managing chemotherapy induced alopecia or cachexia or both, wherein said method consists of administering a composition consisting of pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally using a pharmaceutical excipient, to a subject in need there
1. A method of managing chemotherapy induced alopecia or cachexia or both, wherein said method consists of administering a composition consisting of pentameric type A procyanidin, trimeric procyanidin and tetrameric procyanidin, optionally using a pharmaceutical excipient, to a subject in need thereof; wherein the pentameric type A procyanidin is at concentration ranging from about 55% w/w to about 99% w/w, the trimeric procyanidin and the tetrameric procyanidin are each at concentration ranging from about 0.5% w/w to about 35% w/w, and the pharmaceutical excipient is at concentration ranging from about 0.5% w/w to about 10% w/w. 2. The method as claimed in claim 1, wherein the excipient is selected from the group comprising granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavouring agents, plasticizers, preservatives, suspending agents, emulsifying agents, plant cellulosic material and spheronization agents or any combination thereof. 3. The method as claimed in claim 1, wherein the composition is formulated into a dosage form selected from the group comprising of a tablet, troches, lozenges, aqueous or oily suspensions, capsule, emulsion, spray, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, elixirs, phytoceuticals, nutraceuticals and food stuffs or any combination thereof. 4. The method as claimed in claim 1, wherein the composition is administered to subject in need thereof, at dose ranging from about 1 mg/kg to about 50 mg/kg, preferably ranging from about 10 mg/kg to about 25 mg/kg of body weight of said subject per day. 5. The method as claimed in claim 4, wherein the subject is a mammal.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.